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CB4 – Case 6
EHRGo Link:
https://web21.ehrgo.com/customlink/u/127049/p/212719/n/cb4_2022_c
ase_6

Oncology Diagnosis Clinic Visit (Jun 2)
CC: Referral from PCP
HPI: Margaret Nakamura is a 72 yo female referred form PCP for concern of malignancy. She
reported health changes for the past 2 months, including unintentional 10 lb weight loss,
abnormal fatigue, frequent night sweats, and unexplained abdominal pain. She denies any
recent medical changes and have been adherent to medical appointments and chronic
medications. She claims that her overall health had been great until she experienced abnormal
changes recently that made her worried it might be something serious. She tried eating healthier
food and take a rest more to help with the symptoms. She also took Tylenol and Advil around
the clock for the pain. However, none of them seem to resolve the issues.
PMH: HTN, hypothyroidism, paroxysmal atrial fibrillation
Social History: Widowed. Retired teacher. Lives with son.
Home medications:
Levothyroxine 75 mcg PO daily
Hydrochlorothiazide 25 mg PO daily
Metoprolol tartrate 50 mg PO BID
Rivaroxaban 20 mg PO daily
Acetaminophen 650 mg PO q4h PRN pain
Ibuprofen 200 mg PO q6h PRN pain
Oncologic Assessment:
CT Abdomen ordered by PCP shows enlargement of retroperitoneal nodes as well as small
bowel mesentery nodes.
Vitals:
T: 36.4 °C, HR: 98, RR: 16, BP: 120/78, HT: 5’3”, WT: 148 lb, Pain 8/10
Physical Examination:
GENERAL: pleasant, nontoxic, no acute distress
HEENT: Normocephalic, atraumatic, no scleral icterus or conjunctival injection, preauricular
nodal enlargement noted
NECK: supple, no rigidity. No bruits or thyromegaly
LUNGS: CTA, no wheezing
CV: RRR, normal S1/S2, no gallops. No JVD
GI: nontender, distended, normal bowel sounds
GU: no suprapubic or flank tenderness.
BACK: no spinal or paraspinal tenderness.
EXT: No cyanosis, or distal pitting edema, well perfused. Bilateral digital clubbing without
cyanosis
SKIN: warm and dry, no ulcerations.
NEURO: A&Ox3, cranial nerves 2-12 grossly intact, no gross motor deficits, strength 5/5

bilateral upper and lower extremity large muscle groups, sensation grossly intact throughout to
light touch. DTRs 2+ symmetric at biceps/triceps/knee/ankle.
Assessment/Plan:
Very pleasant 72 years old female with nodal enlargement noted in abdomen and neck.
Preliminary findings may indicate lymphoma. Patient was informed regarding potential
malignancy and the need for further work-up. Patient agreed to continue with recommended
plan. Will schedule lymph node and bone marrow biopsy for further pathologic evaluation and
labs for more work-up. Patient inquire about pain management. Recommend to stop OTC
medications and will initiate hydrocodone/acetaminophen 5/325 mg PO q6h PRN pain. RTC in
1-2 weeks after biopsy.
____________________________________________________________________________

Oncology Follow-up Clinic Visit (Jun 17)
HPI: Margaret Nakamura is a 72 yo female presents to follow-up on biopsies results. referred
form PCP for concern of malignancy. She reports no change in health status since last visit. She
started taking Norco scheduled q6h and claimed that it only helped controlling the pain right
after taking the medications. After 1-2 hours, the effects dissipate and she would be in a lot of
pain and not able to perform daily living activities.
PMH: HTN, hypothyroidism, paroxysmal atrial fibrillation, malignant pain
Social History: Widowed. Retired teacher. Lives with son.
Home medications:
Levothyroxine 75 mcg PO daily
Hydrochlorothiazide 25 mg PO daily
Metoprolol tartrate 50 mg PO BID
Rivaroxaban 20 mg PO daily
Hydrocodone/acetaminophen 5/325 mg PO q6h PRN pain
Oncologic Assessment:
Lymph node and bone marrow biopsy results confirmed Burkitt’s lymphoma
Vitals:
T: 37.2 °C, HR: 92, RR: 12, BP: 124/72, HT: 5’3”, WT: 145 lb, Pain 6/10
Physical Examination:
GENERAL: pleasant, no acute distress
HEENT: Normocephalic, atraumatic, no scleral icterus or conjunctival injection, preauricular
nodal enlargement noted
NECK: supple, no rigidity. No bruits or thyromegaly
LUNGS: CTA, no wheezing
CV: RRR, normal S1/S2, no gallops. No JVD
GI: nontender, distended, normal bowel sounds
GU: no suprapubic or flank tenderness.
BACK: no spinal or paraspinal tenderness.
EXT: No cyanosis, or distal pitting edema, well perfused. Bilateral digital clubbing without
cyanosis
SKIN: warm and dry, no ulcerations.
NEURO: A&Ox3
Assessment/Plan:

Burkitt’s lymphoma
• Pathology findings were explained to patient and we discussed potential treatment options.
• Information about the chemotherapy was provided to patient and benefit and risks of
treatments were discussed.
• Patient agrees to proceed with chemotherapy R-EPOCH. Will plan to schedule first cycle of
chemotherapy. Obtain pre-chemo work-up.
Malignant pain:
• Current pain regimen provide short-term relief
• Initiate oxycodone ER 10 mg PO q12h
• Continue hydrocodone/acetaminophen as needed

Chemotherapy Admission (Jul 5-9)
Admission H&P Day 1 (8 AM)
CC: Chemotherapy initiation
HPI: Margaret Nakamura is a 72 yo female admitted to oncology unit to start chemotherapy for
recently diagnosed Burkitt’s lymphoma. All pre-chemo screenings and work-ups were reviewed
and approved by her oncologist. At presentation, patient was a little bit nervous to start
chemotherapy but otherwise no concern. She reports her pain is still uncontrolled despite
starting oxycodone ER on top of around the clock Norco.
PMH: HTN, hypothyroidism, atrial fibrillation, Burkitt’s lymphoma, malignant pain
Social History: Widowed. Retired teacher. Lives with son.
Home medications:
Levothyroxine 75 mcg PO daily
Hydrochlorothiazide 25 mg PO daily
Metoprolol tartrate 50 mg PO BID
Rivaroxaban 20 mg PO daily
Hydrocodone/acetaminophen 5/325 mg PO q6h PRN pain
Oxycodone ER 10 mg PO q12h
Vitals:
T: 36.9 °C, HR: 82, RR: 15, BP: 122/71, HT: 5’3”, WT: 142 lb, BSA: 1.7, Pain 6/10
Physical Examination:
General: pleasant, no acute distress
HEENT: PERRLA, TMs clear, preauricular nodal enlargement noted
NECK: supple, no JVD
LUNGS: CTA bilaterally
CV: RRR, no MRG
GI: soft, nontender, appears distended, normoactive bowel sounds
EXT: No cyanosis, or distal pitting edema, well perfused
NEURO: A&Ox3
Assessment/Plan:
1. Burkitt’s lymphoma: Pre-chemo work-ups clear. Will initiate R-EPOCH.
2. Malignant pain: Will initiate PCA while inpatient
3. HTN: continue home regimen
4. Hypothyroidism: continue home regimen
5. Atrial fibrillation: continue home regimen

Inpatient Progress Note Day 2 (11 AM)
Impression:
Patient seen today at bedside. No acute event overnight. Received 29.7 mg IV morphine over the
past 24 hours and patient reports significant improvement in pain.
PE:
HEENT: PERRL, EOMI, TMs intact
Resp: CTA bilaterally
CV: RRR, no MRG, (-) JVD
Abd: soft, nontender, unchanged distention, normoactive bowel sounds
Ext: Skin intact, peripheral pulses palpable, no erythema or rash
Neuro: A&Ox3, non-focal, cranial nerves intact
Assessment/Plan:
Day 1 chemotherapy completed without issue. Continue day 2 chemotherapy.
Inpatient Progress Note Day 3 (11 AM)
Impression:
RN reports no event overnight. Pain control stable with 30.3 mg IV morphine received in 24
hours.
PE:
HEENT: PERRL, EOMI, TMs intact
Resp: CTA bilaterally
CV: RRR, no MRG, (-) JVD
Abd: soft, nontender, unchanged distention, normoactive bowel sounds
Ext: Skin intact, peripheral pulses palpable, no erythema or rash
Neuro: A&Ox3, non-focal, cranial nerves intact
Assessment/Plan:
Day 2 chemotherapy completed. Continue day 3 chemotherapy.
Inpatient Progress Note Day 4 (11 AM)
Impression:
No acute event overnight. Per RN, patient doesn’t have much appetite since last night. Patient
reports feeling nauseated and "fullness in the stomach". No complaint for pain and received 29.4 mg
IV morphine in the last 24 hours.
PE:
HEENT: PERRL, EOMI, TMs intact
Resp: CTA biltaterally
CV: RRR, no MRG, (-) JVD
Abd: soft, nontender, unchanged distention, normoactive bowel sounds
Ext: Skin intact, peripheral pulses palpable, no erythema or rash
Neuro: A&Ox3, non-focal, cranial nerves intact
Assessment/Plan:
Day 3 chemotherapy completed. Continue day 4 chemotherapy. Initiate metoclopramide 5 mg
IV q6h PRN for nausea
Discharge Note Day 5 (4 PM)
Reason for Admission: Chemotherapy initiation for Burkitt’s lymphoma

Hospital Course:
Patient is a 72-year-old female with PMH of Burkitt’s lymphoma, chronic pain, HTN,
hypothyroidism, and atrial fibrillation. Patient completed first cycle of R-EPOCH without
complication. She experienced several episodes of nausea/vomiting but otherwise no other
complaint. Primary oncologist is aware of hospital course. Patient feels she is doing fine and
requested to be discharged after completing the chemotherapy.
PE:
GENERAL: Nontoxic, no acute distress
HEENT: Normocephalic, atraumatic, no scleral icterus or conjunctival injection
NECK: supple, no rigidity. No lymphadenopathy.
LUNGS: CTA bilaterally. No crackles or wheezes.
CV: RRR, no MRG
GI: soft, nontender, decreased distention, normal bowel sound
GU: no suprapubic or flank tenderness.
BACK: no spinal or paraspinal tenderness.
EXT: No cyanosis, clubbing or distal pitting edema, well perfused.
SKIN: warm and dry, no ulcerations
NEURO: A&Ox3, cranial nerves intact
Discharge Plan:
1. Burkitt’s lymphoma: Complete 1st chemotherapy cycle. Monitor health status at home. Followup with primary oncologist within a week.
2. Malignant pain: Stable during admission on PCA. Continue home pain regimen and refer to
pain clinic for management.
3. Nausea/vomiting: Likely acute due to chemotherapy. Prescribe metoclopramide as needed
for discharge.
4. HTN: continue home regimen
5. Hypothyroidism: continue home regimen
6. Atrial fibrillation: continue home regimen

Emergency Admission Day (Jul 13)
Admission H&P (10:10 AM)
CC: Cardiac arrest
HPI: Margaret Nakamura is a 72 yo female BIBA post-cardiac arrest. She was having a morning
walk with her son when she suddenly collapsed. Her son, who is a firefighter, found her with no
pulse and immediately performed CPR before paramedic arrived and took over. Paramedic
found her with ventricular fibrillation and successfully resuscitated her after 5 rounds of CPR.
She was also intubated on the field. Her son reports that she was recently diagnosed with
Burkitt lymphoma and was admitted to receive her first chemotherapy cycle. Since being
discharged, she has been feeling very weak and no appetite at all. She tried eating but she gets
nauseated and had vomited few times. She is also in a lot of pain despite taking her pain
medications around the clock.
PMH: HTN, hypothyroidism, atrial fibrillation, Burkitt lymphoma, chronic malignant pain
Social History: Widowed. Retired teacher. Lives with son.

Home medications:
Levothyroxine 75 mcg PO daily
Hydrochlorothiazide 25 mg PO daily
Metoprolol tartrate 50 mg PO BID
Rivaroxaban 20 mg PO daily
Hydrocodone/acetaminophen 5/325 mg PO q6h PRN pain
Oxycodone ER 10 mg PO q12h
Metoclopramide 5 mg PO q6h PRN N/V
Physical Exam:
Vitals: BP 84/42, T 38.7o C, P 62, RR 12, Wt 140 lb, Ht 5’3”
General: sedated and unresponsive
HEENT: Normocephalic, atraumatic, no scleral icterus or conjunctival injection, preauricular
nodal enlargement noted
Neck: No tenderness, masses, or stiffness, no JVD
Lungs: Mechanical breath sounds appreciated to auscultation and percussion, non-labored
respiration. Symmetrical chest expansion which is synchronous with the vent
CV: RRR, normal rate, no edema
Abdomen: Distended, decreased bowel sounds, tenderness to touch
Extremity: no cyanosis, clubbing, or distal pitting edema
Skin: intact, dry, no rash or lesions
Neurologic: unresponsive on sedation
Assessment/Plan:
1. Cardiac arrest: Likely due to electrolyte abnormalities 2/2 tumor lysis syndrome. Initiate postcardiac arrest care protocol and treat causes. On mechanical ventilation. Goal MAP >65. Admit
to ICU.
2. Sepsis/febrile neutropenia: Completed first cycle of R-EPOCH. Possible GI source. Obtain
CT abdomen and initiate empiric antibiotics.
3. HTN: Consult pharmacy to reconcile home med
4. Hypothyroidism: Consult pharmacy to reconcile home med
5. Atrial fibrillation: Consult pharmacy to reconcile home med
Imaging
ECG: QTc 429, normal rhythm
CT Head: normal, no infarct/bleeding
Chest X-ray: normal, no sign of infection or abnormality. Appropriate placement of ET tube.
_______________________________________________________________________
Summary of Labs/Vitals/Cultures:
Actual BW: 63.6.9 kg
IBW: 52.4 kg (BMI 25.7)
Labs:
CBC

WBC (cell/ml)
Hgb (g/dl)
Hct (%)
Plt (x103/uL)
MCV
MCH
MCHC

Dx
Visit
(Jun 2)
4100
12.2
36.8
156
96.5
31
33.2

Chemo
Day 1

Chemo Chemo Chemo
Day 2
Day 3
Day 4

5300
12.5
37.2
178
95.8
33
32.8

5400
12.4
36.9
168

4900
12.1
35.8
162

4600
12.7
36.9
158

Chemo
Day 5
Admission
(Day 9)
4100
750
12.2
9.1
35.9
28.2
156
82
82
32
34

Bands (%)
3
5
Segments (%)
58
62
Lymph (%)
24
26
Mono (%)
3
5
Eos (%)
1
3
Baso (%)
1
1
Coag
PT (s)
12
11
INR
0.9
1
PTT (s)
24.8
23.2
Anti-Xa (U/mL)
0.15
CMP
Na (mEq/l)
136
141
140
142
K (mEq/l)
4.2
3.9
4
3.9
Cl (mEq/l)
98
101
99
102
CO2 (mEq/l)
26
26
24
23
Glu (mg/dl)
101
99
103
97
BUN (mg/dl)
19
18
19
16
SCr (mg/dl)
1
0.7
0.8
0.8
**CrCl (ml/min) 54
74
64.8
64.8
Ca
8.6
8.7
P
3.5
3.7
Mg
1.6
1.9
Tbili (mg/dl)
0.4
0.3
ALT (IU/l)
22
11
AST (IU/l)
36
20
Alkphos (IU/l)
87
53
Albumin (g/dl)
2.8
2.9
LDH (U/L)
320
346
Lactate
(mmol/L)
Troponin
(ng/mL)
BNP (pg/mL)
Uric
acid 6.2
6.3
(mg/dl)
G6PD (U/g Hb)
10.2
Blood cultures
Urinanalysis
negative
Urine culture
TSH
2.3
ABG
pH
PaCO2
HCO3PaO2
**CrCl not provided, students have to calculate.

13
15
27
5
1
1
11.9
1.1
25.4
0.14
143
4.3
98
26
92
17
0.9
57.6

137
4.5
97
22
85
20
1
51.8

140
6.5
105
17
139
39.6
1.7
30
8.5
4.2
2.4
0.3
27
51
97
3.2
2.2
<0.01 x2
98
8.2

pending
Negative
pending

7.31
38
16
80

Vitals: Vitals included in outpatient visits and each admission notes. During chemotherapy
admission, vitals are all normal. Meals consumed during chemo admission was also included.
Mostly showing normal appetite on day 1&2 and slowly deteriorate on day 3-5 due to CINV.

Pain Scales:

Medications ordered on chemotherapy admission
Chemotherapy: rituximab (day 1), etoposide +vincristine + doxorubicin (day 1-4), prednisone 50
mg BID (day 1-5), cyclophosphamide (day 5)
PCA: morphine basal 0.7 mg/hr, intermittent 0.3 mg q15min (average ~30 mg/24 hr)
Continue home rivaroxaban, metoprolol, levothyroxine, HCTZ
Recent vaccines:
- Flu (11/15/2021)
- COVID (05/11/21, 7/1/21, 11/15/2021)

Student Instructions
1. Please provide complete SOAP for the main problems with specific instructions as follows.
a. ACLS/Tumor lysis syndrome: provide plan for post-cardiac arrest care to include
maintaining hemodynamic stability and treating the causes of cardiac arrest

b. Febrile neutropenia/suspected intraabdominal infection: provide assessment and plan
for inpatient treatment
2. Please provide assessment and plan on secondary problems and recommend appropriate
vaccinations
3. Please review patient’s course of hospitalization and recent hospitalizations (including
appropriateness of medications initiated, monitoring during hospitalization, or any necessary
follow-ups) to assist in responding to the OOB questions
4. Please utilize appropriate protocols or antibiogram and be mindful of available drug
strengths/forms to devise appropriate treatment plan

1. ACLS/Tumor Lysis Syndrome
S:
collapsed out-of-hospital and found with no pulse by son who performed CPR
O:
resuscitated by paramedics prior to arrival and intubated, recent completion of chemo for
Burkitt’s lymphoma, vitals, ABG, K, SCr, uric acid, lactate, troponin undetected
A:
1. Cause of cardiac arrest are likely due to hyperkalemia/acidosis secondary to TLS
2. Currently hemodynamically unstable (MAP 56) post-cardiac care and fluid therapy and
subsequent vasopressors are needed to maintain stable hemodynamics
3. High risk for TLS given Burkitt’s lymphoma and recently completed chemotherapy
4. Met the laboratory and clinical TLS given uric acid >8, K >6, experiencing arrhythmia, and
elevated SCr
Goals for Therapy: 1) MAP >65, 2) maintain adequate tissue perfusion to prevent end-organ
damage, 3) correct electrolyte imbalance and acidosis, 4) treat hyperuricemia
Guideline: 2016 SCCM Surviving Sepsis Campaign: International Guidelines for Management
of Sepsis and Septic Shock, 2015 AHA Update for CPR and Emergency CV Care: Post-Cardiac
Arrest Care, 2008 ASCO/Journal of Clinical Oncology Guidelines for the Management of
Pediatric and Adult TLS: An Evidence-Based Review

P:
1. NS or LR 2-3 L/m2/d (3.4-5.1 L/d) – may include bolus 30 ml/kg (~2L)
+/- Vasopressors:
• Norepinephrine 0.1-0.5 mcg/kg/min or 5 mcg/min titrate q2-5 min (preferred)
• Dopamine 5-10 mcg/kg/min
• Epinephrine 0.1-0.5 mcg/kg/min or 5 mcg/min titrate q2-5min
2. Insulin regular 10 units IV bolus x1 with 25-50 g dextrose OR sodium bicarbonate 50 mEq IV
x1 bolus
3. DC HCTZ
4. Rasburicase 0.2 mg/kg (12-13.5 mg) IV daily 1-7 days OR singe dose of 3-10.5 mg IV x1 with
repeat 1.5-6 mg IV x1 dose based on subsequent uric acid levels
Non-pharm: mechanical ventilation (to maintain oxygenation)
Patient education: ADE (insulin: hypoglycemia; rasburicase: peripheral edema, headache,
anxiety, rash, N/V/D, constipation, increased LFT)
Monitoring/Follow-up: Vitals q1-2h while hemodynamically unstable/in ICU, I/O every shift,
electrolytes (K, P, Ca, SCr, uric acid) q8-12h until TLS resolves/trend down, ADE daily
Rationales
Recommendation
Fluid +/- Vasopressor
Hyperkalemia treatment
DC HCTZ
Rasburicase

Rationale
Patient is hemodynamically unstable/hypotensive and will need to
target MAP >65
K is elevated and will need to be normalized to prevent another
cardiac events/arrhythmia
HCTZ can cause hyperuricemia
Patient is experiencing TLS and have high uric acid. Rasburicase is
preferred over allopurinol due to MOA that convert uric acid to soluble
metabolite to prevent crystallization and cause organ damage.

Allopurinol acts by inhibiting uric acid formation, which won’t help
much when uric acid is already produced and at high plasma levels,
causing complications.

2. Febrile Neutropenia
S: started feeling sick after chemotherapy
O: T, BP, WBC, segment, band (ANC = 750 x [0.13 +0.15] = 210), BCx pending, Abdomen PE
distended, tender to touch
A:
1. Patient is experiencing febrile neutropenia given ANC<500 and a single oral T of >38.3C
2. Patient is clinical unstable and septic and recently hospitalized for chemotherapy
administration thus warranting pseudomonal and MRSA coverage.
3. Anaerobe coverage should be considered empirically given suspected GI source.
Goal of Therapy:
Treat febrile neutropenia, prevent recurrence, minimize risk of infections,
minimize further bone marrow suppression, AUC 400-600 or trough 15-20
Guidelines: Clinical Practice Guideline for the Use of Antimicrobial Agents in Neutropenic
Patients with Cancer: 2010 Update by the IDSA, 2022 NCCN Clinical Practice Guidelines in
Oncology Prevention and Treatment of Cancer-related Infections
Plan:
1. Cefepime OR ceftazidime 2 g IV q12h
• Zosyn (79%) have lower susceptibility for Pseudomonas
• Carbapenem and Fluroquinolones are restricted
2. Metronidazole 500 mg IV q8h
3. Using AUC monitoring: Vancomycin IV 750 mg q18-24h, 1000 mg q36h
Using trough monitoring: Vancomycin IV 1000-1250 mg q24h
Explanation if students only use Lexicomp resource without accounting AKI setting:
Vancomycin 15-20 mg/kg q8-12h recommended. However, it’s for normal renal function.
These doses will be too much for this patient in AKI.
Trough monitoring calculations:
Vd = 0.8 L/kg x 63.6 kg = 50.9 L
CrCl = (140-72)x 63.6 x 0.85 = 30 ml/min
72x1.7
Vanco CL = 30x0.06 = 1.8 L/hr
k = 1.8/50.9 = 0.035 hr -1
t1/2 = 0.693/0.035 = 19.8 hr
Peak should not exceed 50 mcg/ml
Equation = tr + (Dose/Vd)
Dose 1000 mg q24h (tr 14.8, peak 34.1)
Dose 1250 mg q24h (tr 18.5, peak 43)

4. DOT: depend on infection source once confirmed (4-7 days for intraabdominal infection) or
at least until ANC>500 if unknown source
5. Tylenol 325-650 mg q4-6h PRN for fever

Non-pharm: Hygienic habit
Patient education:

precautions to minimize infection risks in immunocompromised patients

Monitoring/Follow-up: T q4-8h, CBC/SCr/BCx/ADE daily. Obtain vancomycin trough prior to
3rd dose or peak of 2nd dose and trough prior to 3rd dose for AUC
Rationales
Recommendation
Empiric therapy

Rationale
For patient with febrile neutropenia requiring IV antibiotics,
antipseudomonal coverage is warranted. Per antibiogram,
cefepime/ceftazidime has better susceptibility compared Zosyn. In
addition, given patient is hemodynamically unstable and recent
hospitalization, vancomycin should be added as well. Given suspicion
GI source, anaerobe coverage will be needed as well. Antibiotics
should be continued until ANC >500 or throughout recommended DOT
once source is confirmed.

3. SECONDARY PROBLEMS
1. Oncology supportive care (pain, CINV, BMS): Defer to OOB questions below
2. HTN: Refer to OOB questions below
3. Hypothyroidism: Refer to OOB questions below
4. Atrial fibrillation: Refer to OOB questions below
5. Vaccination (after acute illness resolution): COVID 2nd booster, Tdap/Td q10years (if
indicated), Shingrix (2 doses 2-6 months apart), PCV 15 then PPV23 1 year later or
PCV20 only

OOB QUESTIONS
1. (a) Do you agree with the antiemesis regimen Margaret was started during the
chemotherapy cycle? If not, what would you recommend differently?
• Patient’s chemotherapy contain agents (doxorubicin <60 mg/m2 and cyclophosphamide
<1500 mg/m2) that have moderate emetic risk so patient is indicated for prophylaxis.
• Recommended prophylaxis (3 options):
o As part of patient chemotherapy, patient is receiving prednisone 50 mg PO BID,
which is equivalent to dexamethasone 15 mg/day so technically patient has met the
steroid dose needed for antiemesis prophylaxis purpose for any option below

(b) Provide assessment and plan for Margaret regarding the indication for cancer-related
infection prophylaxis (including antimicrobial/antifungal/antiviral agents and/or growth
factors) based on her malignancy and chemotherapy.
• Assessment: Lymphoma has intermediate risk for overall infection risk in patients. Per
guideline, antibiotic prophylaxis is indicated for her during neutropenia. Antifungal
prophylaxis/PJP is not considered for lymphoma unless patient underwent HCT, while
antiviral prophylaxis for HSV should be considered as lymphoma has intermediate risk.
Prophylactic use of CSF is indicated for the patients as risk with current chemotherapy
regimen is high (>20%).
• Plan:
o Antibacterial PPx: levofloxacin 500-750 mg PO daily or ciprofloxacin 500-750 mg BID
until neutropenia resolves
o Antiviral PPx: acyclovir 400-800 mg PO BID or famciclovir 250 PO BID, or
valacyclovir 500 mg PO BID until neutropenia resolves or possibly longer depending
on degree of immunosuppression
o CSF: filgrastim 300 mcg SC daily until ANC>10,000 or for up to 14 days or
pegfilgrastim 6 mg SC x1 starting the next day after completion of chemotherapy or
up to 3-4 days after.
(c) What screening or pre-chemo work-up should be conducted prior to Margaret’s
chemotherapy? Consider type of malignancy, ADE, precautions, contraindications, safety,
etc. of R-EPOCH.
• Baseline CBC as the chemotherapy has overall myelosuppression side effects

•
•
•
•
•

Renal function: cyclophosphamide has risk for hemorrhagic cystitis & risk of TLS in
Burkitt’s lymphoma
Hep B & TB screening particularly when MAb like rituximab is prescribed
ECG and Echocardiogram/LVEF before starting any anthracycline like doxorubicin
(cyclophosphamide also has been associated with reports of cardiotoxicity)
LFT as rituximab may increase LFT or cyclophosphamide may cause hepatotoxicity
Uric acid & Ca given risk of tumor lysis syndrome and hypercalcemia

2. (a) Provide assessment regarding Margaret’s pain management prior to receiving
chemotherapy (include rationales if you agree or disagree with how her pain was managed
with initial PRN hydrocodone/acetaminophen then adding the oxycodone ER).
• Margaret’s initial presentation in regards to pain is severe (8/10), affecting her ADLs, and
uncontrolled despite taking analgesics Tylenol and ibuprofen around the clock. Per
NCCN guideline, for cancer pain in opioid-naïve patients, given the pain is severe, she
can be started on Norco 5/325 mg as much as q4h PRN. At the follow-up visit, her pain
is slightly improved but still moderate intensity despite taking the PRN opioids around
the clock. It is reasonable to consider long-acting opioid especially she was complaining
that the effect of Norco was not long-lasting. Dose-wise Norco around the clock (5 mg
q6h) gets her to 20 mg MME. She was then started on oxycodone ER 10 mg q12h (=30
MME). Students may disagree as this is a big jump. Pain was not controlled at 20 mg
MME, it may be increased 25-50% but there is also cross-tolerance needs to be
considered at 25-50%, which brings the dose to about oxycodone 10-15 mg/day.
(b) Do you agree with the PCA set-up for Margaret during hospitalization for chemotherapy
(include rationales and if you have different recommendations)?
• At this point, Margaret are on oxycodone ER 10 mg q12h + Norco 5/325 mg q6h around
the clock and pain is still uncontrolled before oxycodone started. This is equivalent to 50
MME. Dose can be titrated up but cross-tolerance should also be considered as the
patient was switched to get morphine PCA, which brings the TDD for PCA to be about
30-56 MME. This further is divided by 3 to convert to IV morphine (~10-19 mg IV
morphine). To calculate PCA doses, TDD is divided by 24 to get the basal rate in mg/hr
(~0.4-0.8 mg/h) and then the demand/intermittent dose is 50% of hourly rate (0.2-0.4
mg) allowed PRN q8-15 min. The PCA set-up for her was basal 0.7 mg/hr with 0.3 mg
q15min, which is in the calculated dose ranges.
(c) What pain regimen would you have recommended for Margaret at discharge after
completing the chemotherapy?
• During hospitalization Margaret was on average receiving 30 mg IV morphine (= 90
MME) to control pain. It’s almost double her home dose 50 MME. So at discharge, her
pain regimen should be increased. Considering 25-50% cross-tolerance, her TDD can
be around 45-67.5 MME. She needs more than 50 MME as it is not controlling her pain
well. One way to change the regimen is to increase oxycodone ER dose to 30 mg/day
(15 mg q12h or 10 mg qAM + 20 mg qPM or 10 mg q8h but less preferred than q12h)
that increase the total MME (in addition to Norco 5/325 mg q6h) to 65 mg. Another way
is to increase PRN doses to 10/325 mg q6h and keep the oxycodone 10 mg q12h that
brings up the MME to about 70. All depends on patient description of the pain too.

3. Describe step-by-step how 5 rounds of CPR would look like to resuscitate Margaret from
cardiac arrest with ventricular fibrillation rhythm. Include all non-pharmacological and
pharmacological interventions you, the pharmacist, would recommend as part of the ACLS
resuscitation effort. Consider the timing, quality/roles of interventions to prioritize, and
causes of cardiac arrest with their treatments.
• The 2 interventions that has been shown to
improve survival to discharge (and critical to be
uninterrupted) are high-quality CPR and
defibrillator/shock for shockable rhythm so these
should be prioritize first before medications (i.e. CPR
first then epinephrine or shock first then try
amiodarone)
• High-quality CPR criteria: at least 2 inches depth,
>100 compression/minute, allow chest recoil, limit
interruptions to <10s, rotate compressor q2min
• Ventilation with airbag if no advanced airway
(mostly out-of-hospital)
• Medications:
o Epinephrine 1 mg IV/IO q3-5 min
o For shockable rhythm only: amiodarone 300 mg
IV/IO bolus then if still not resuscitated can
administer another 150 mg
• Always think about causes (5H/5T) and treat when
able
o Hypovolemia: fluid
o Hypoxia: advanced airway
o Hydrogen ions (acidosis): sodium bicarb +
identify causes of acidosis
o Hypo/hyperkalemia: K for hypo; insulin/sodium
bicarb for hyperkalemia, calcium chloride for
heart stabilization
o Hypothermia: warm blanket/fluid after ROSC
o Tension pneumothorax: surgical intervention
after ROSC
o Tamponade: surgical intervention after ROSC
o Toxins: antidotes if available
o Thrombosis (pulmonary): fibrinolytics if
massive/submassive
o Thrombosis (coronary): cath lab after ROSC
4. (a) The provider is asking your help to reconcile Margaret’s home medications. Since
Margaret is intubated, she is not able to take PO medications. Provide assessment and plan
for Margaret’s home medications to be reconciled at the time of admission (include
assessment if medications are indicated or can be appropriately resumed).
• Levothyroxine: Recent TSH (within ~1 month) is at goal. Continue and switch to
levothyroxine IV at dose 50-80% of PO dose = 37.5-60 mcg/day
• Hydrochlorothiazide/metoprolol tartrate: hold while hypotensive. HCTZ should be
discontinued due to hyperuricemia as well
• Rivaroxaban: CHADS2Vasc score is 3 (HTN + age + female), anticoagulation is
indicated. May recommend continuing anticoagulation. Student may also argue that risk
may outweigh benefit at this point due to higher bleeding risk due to myelosuppression

(low Hgb/Plt) so delay anticoagulation at this time. If continuing anticoagulation, student
needs to recommend heparin gtt 60 u/kg x1 (4000 units) bolus then 12u/kg/hr (790u
u/hr) continuous infusion OR Lovenox 1 mg/kg (60 mg) SC q12h
• Opioids: Analgesia as part of the ICU and intubation care (see part (b) below)
• Metoclopramide: IV available 1:1 conversion. May continue PRN although less likely
patient would be needing it while intubated/sedated.
(b) Provide assessment, potential treatment/interventions, and monitoring plan for optimal
ICU care (i.e. address FASTHUG BID).
• Feeding: ensure optimal fluid management for hemodynamic stability and
collaborate with MD/RD to start feeding when appropriate
• Analgesia: given intubation and underlying chronic pain, patient should be started
on analgesia and monitor CPOT with goal 0-2 or behavioral pain scale with goal 3-5
(observing objective data in ICU such as facial expression/body movement/muscle
tension/ventilation compliance/vocalization for pain control). Analgesia options
include fentanyl/hydromorphone drip
• Sedation: given intubation, sedative agent may be warranted to achieve goal RASS
of -2 to 0 (light sedation) or Riker SAS 4 (calm/cooperative). Sedation options
propofol, dexmedetomidine, or midazolam.
• Thromboprophylaxis: patient at high risk for VTE (i.e. atrial fibrillation, malignancy).
Student may argue high risk for bleeding as well (i.e. low Hgb/Plt). May hold
chemical prophylaxis and initiate SCD instead OR if continuing anticoagulation for
Afib, may start heparin gtt as above. Plans & benefit/risk will need to be discussed
with provider (typically some providers are ok with anticoagulants if there are
indications until Plt<50).
• Hyperactive/hypoactive delirium: high risk for delirium due to intubation and age.
Minimize risk such as early frequent re-orientation, engagement, promoting good
sleep and minimize interruption, avoid BZD if possible. Monitor frequently and
assess CAM-ICU when able.
• Ulcer prophylaxis: depending on intubation period, patient might need ulcer
prophylaxis. Common options are pantoprazole or famotidine.
• Glucose control: Maintain BG 140-180 while inpatient. May start sliding scale
insulin if needed.
• Bowel movement: patient needs bowel care with previous signs and symptoms of
constipation and being on chronic opioids. Start bowel care. Typically first-line
docusate/senna. Rectal formulation/enema while intubated/NPO.
• Indwelling catheter OR imbalance electrolyte/fluid: precaution for infection
prevention with existing catheter, maintain fluid therapy for hemodynamic stability,
maintain electrolytes and treat as necessary (i.e. hyperkalemia)
• Drug de-escalation (can be delirium too – see above): Continue to follow empiric
treatments and narrow therapy when applicable

Problem #1 ACLS
1. What’s the role epinephrine in cardiac arrest (not where it fits on algorithm, how does it
work/the purpose specifically in cardiac arrest ---think MOA)?
• Epinephrine is vasopressor used in cardiac arrest for its alpha-adrenergic effects (i.e.
vasoconstrictor). These effects increase coronary and cerebral perfusion pressure
during CPR.
2. When would you consider using calcium chloride/gluconate in a cardiac arrest patient? What
is the MOA? What is the difference between the chloride/gluconate formulation?
• When cardiac arrest is caused by HyperK or HyperMg

•
•

MOA: Stabilize heart as it antagonizes cardiac conduction abnormalities in the setting of
hyperkalemia (not redistributing K into cells)
Gluconate vs. chloride: There are 3-4x more elemental calcium in calcium chloride.
However, there is high risk of phlebitis and in non-emergency setting, calcium gluconate
is preferred, otherwise, calcium chloride is recommended to be delivered through central
line unless it’s used in emergency situation and patient is unresponsive

3. When do you use amiodarone in ACLS? Where does it fit and how does it work/the purpose
specifically in cardiac arrest)? How does amiodarone administered in non-emergency
setting?
• Amiodarone is an antiarrhythmic drug used in cardiac arrest to convert pVT/VF to an
organized perfusing rhythm.
• It’s used during ACLS when pVT/VF persists or recurs after 1 or more shocks
(refractory).
• Administration: In emergency setting, it’s given IV bolus peripherally. In non-emergency
setting, it is usually given as a continuous infusion in D5W bag and non-PVC bag as it is
only compatible in D5W and can leach on PVC bag. Central line administration is
preferred if possible as it does have risk of phlebitis.
4. When would you consider using sodium bicarbonate in a cardiac arrest patient?
• To correct acidosis that cause cardiac arrest.
• For Hyperkalemia management as it shifts serum K into cells.
5. In the case that IV access can’t be obtained, what alternative routes can be used and what
medications can be administered via other routes?
• Intraosseous (injecting directly to the bone) – epinephrine, amiodarone
• Endotracheal tube – epinephrine, vasopressin, lidocaine can be substituted for
amiodarone
i. FYI (least preferred route when nothing else works and need 2-2.5x doses compared
to IV/IO given less absorption anticipated)

Problem #2 Febrile Neutropenia
6. What is the definition of febrile neutropenia?
• ANC ≤ 500/mm3 + Temp. ≥ 101˚F (≥38.3˚C) of a single oral temperature OR
• ANC ≤ 500/mm3 + Temp. > 100.4˚F (≥38.0˚C) 2 consecutive readings 1 hour apart
7. How is ANC calculated?
• ANC = WBC x % granulocytes (Segs + Bands)
8. What are risk factors of high-risk febrile neutropenia?
• Anticipated prolonged (>10 days) and profound (ANC ≤100/mm3 ) neutropenia
• Age >65 y.o.
• Sepsis syndrome
• Pneumonia or other clinically documented infections.
• Invasive fungal infection.
• Hospitalization at the time of fever
• Prior episode of febrile neutropenia.
9. What is MASCC score and what does the score indicate?
• Used to help identify patients with low risk febrile neutropenia

• Score of >21 is likely to be at low risk for complications and morbidity thus can proceed with
outpatient treatment

•
•

What are the recommendations to manage high-risk febrile neutropenia?
Inpatient IV antibiotics with empiric antipseudomonal coverage

10. Is vancomycin always recommended for high-risk febrile neutropenia?
• No, unless there is evidence of cellulitis or pneumonia or if patient is clinically unstable
11. What is the antibiotic duration of treatment for febrile neutropenia?
• If source/microorganism is known, it will depend on source
• If unknown, continue antibiotics until at least ANC >500
12. When are prophylactic antibiotics, antifungal, and antiviral indicated?
• When patient remain neutropenic after completing antibiotic treatment
• When patient with cancer has intermediate or high risk for infections based on the disease
type, treatment plan, and chemotherapy regimen
Secondary Problems
13. What is the role of colony-stimulating factors and when is it indicated?
• Serve as prophylaxis to reduce incidence, magnitude, and duration of neutropenia when
chemotherapy regimen has incidence of febrile neutropenia of >20%)
14. What is the mechanism of actions of filgrastim?
• Stimulates production of neutrophilic granulocytes
15. What are ADRs of filgrastim?
• Bone pain, risk of secondary malignancy while on chemotherapy (MDS and AML), splenic
rupture, acute respiratory distress syndrome, allergic reactions, alveolar hemorrhage,
hemoptysis
16. What are the difference between filgrastim and pegfilgrastim administration?

• Pegfilgrastim has a long half-life and should not be administered within 14 days prior to
chemotherapy or until a day after. Filgrastim should not be administered within 24 hours
before and after chemotherapy.
17. What is the CBC threshold to initiate or resume chemotherapy regimen that may cause
bone marrow suppression?
• ANC >1,500 or WBC >3 AND Plt >100,000
18. How are pain assessed clinically?
• Type: nociceptive (pain from damage to non-neural tissue due to activation of
noceiceptors) vs. neuropathic (caused by lesion or disease of the nervous system)
• Etiology: trauma, inflammatory, idiopathic, malignant
• Time course: Acute vs chronic
• Pain severity scale 1-10 (10 being most severe intensity)
• Location/anatomical site
• Impact: physical, psychological, social, functioning
• PMH, surgical/psychological/medication history related to pain
• Prior pain management and control
• Pain characteristics (sharp/dull, burning, ache, localized/generalized)
19. What are typical treatment options for nociceptive pain?
• Acetaminophen, NSAIDS, opioids
20. What are ADRs of opioids?
• Constipation, respiratory depression, sedation, pruritus
21. What are BBW of opioids?
• Risk of addiction, abuse, and misuse
• Life-threatening respiratory depression
• Neonatal opioid withdrawal syndrome
• Increased risk of CNS depressants when used with benzodiazepine
• Accidental ingestion
• CYP450 interactions (specifically with hydrocodone, oxycodone, methadone)
22. How do you calculate MMEs for opioids?
• Calculate the total daily doses of all current opioids medications and convert to MMEs by
multiplying dose by conversion factors below

23. Which opioids do not have linear conversion?

• Fentanyl: Converting other opioids to fentanyl is specific to dose conversion
recommendations from the package insert

• Methadone: conversion factors increase with increasing dose when converting from
methadone to MME (see conversion table in previous question)
24. What are some risk factors of opioid overdose?
• Opioid use disorder history, highly prescribed dose of opioids, concomitant use of CNS
depressants (i.e. alcohol, illicit substances, BZD, barbiturates), preexisting liver/lung
diseases, mental health disorders, history of previous overdose
25. What are the different type of emesis and what are their definition?
• Acute: occurs within 24 hrs after chemotherapy or radiation
• Delayed: occurs 24 hrs or more after chemotherapy or radiation
• Anticipatory: occurs before chemotherapy or radiation
• Breakthrough: occurs despite of prophylactic treatment and/or requires rescue
antiemetic agents
• Refractory: occurs despite of antiemetic treatment
• Radiation-induced: occurs more commonly with whole body or upper abdominal
radiation
26. What are risk factors of CINV?
• History (esp. n/v with prior chemotherapy or radiation or with pregnancy, motion
sickness)
• Gender: female >male
• Age: younger age (≤50 yrs)
• No or minimal history of alcohol use
• Anxiety
• Specific chemotherapy regimen or radiation site
27. What is the MOA of dopamine receptor agonist for CINV? Please provide example of agent
under this class and ADRs to watch out for.
• MOA: inhibit dopamine receptors at the chemoreceptor trigger zone
• Agents: metoclopramide, prochlorperazine, promethazine, haloperidol
• ADR: extrapyramidal syndrome (i.e. dystonia, akathisia, tardive dyskinesia), CNS
depression, QT prolongation
28. What is the MOA of atypical antipsychotic for CINV? Please provide example of agent under
this class and ADRs to watch out for.
• MOA: antagonize dopamine and serotonin receptors to provide antiemetic effect
• Agents: olanzapine

• ADR: neuroleptic malignant syndrome (i.e. hyperpyrexia, muscle rigidity, altered mental
status, autonomic instability), tardive dyskinesia, orthostatic hypotension, metabolic
syndrome (hyperglycemia, hyperlipidemia, weight gain), CNS depression
29. What is the MOA of serotonin (5HT3) receptor antagonist for CINV? Please provide example
of agent under this class and ADRs to watch out for.
• MOA: block serotonin receptors peripherally in GI tract and centrally at chemoreceptor
trigger zone
• Agents: ondansetron, palonosetron, granisetron, dolasetron, alosetron
• ADR: QT prolongation, headache, constipation
30. What is the MOA of substance P/neurokinin-1 (NK1) antagonist for CINV? Please provide
example of agent under this class and ADRs to watch out for.
• MOA: Antagonize substance P and block NK1 receptors to inhibit pathogenesis of emesis
• Agents: aprepitant, rolapitant, neutpitant, fosnetupitant, fosaprepitant
• ADR: dizziness, moderate fatigue, headache, hiccups, mild/transient LFT elevations

